Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.37 |
| ▸ | DUT | P33316 | 3/20 | 0.36 |
| ▸ | TK1 | P04183 | 2/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599951 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10172061 | 1.00 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10523021 | 0.91 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL28629420 | 0.88 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9310399 | 0.87 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10338226 | 0.84 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9471434 | 0.84 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL9470725 | 0.84 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10515384 | 0.84 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10465785 | 0.84 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | HAVCR2, PNP, PCNA | SLC28A1 54/4885SLC28A2 43/4885SLC29A1 12/4885 |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | HAVCR2, PNP, DCTD | SLC28A1 78/4885SLC28A2 50/4885SLC29A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.